Teams link: Join the meeting now

Meeting ID: 277 080 580 861 9

Passcode: nk3a6S6b

Learning Objectives: 

  • Outline briefly what allogenic HSCT is and current therapies for preventing acute GVHD​

  • Summarize pertinent characteristics of ATG​

  • Evaluate select primary literature for the use of ATG in acute GVHD prevention​

  • Interpret pharmacokinetic-guided ATG dosing proposed in the PARACHUTE Trial​

Session date: 
03/12/2026 - 2:00pm to 3:00pm CDT
Location: 
In-person and Virtually
Will be determined by room availability
600 Highland Ave
Madison, WI 53705
United States
See map: Google Maps
  • 1.00 ACPE Contact Hours - Pharmacist
  • 1.00 University of Wisconsin–Madison Continuing Education Hours
Add to calendar: 
Please login or register to take this course.
Discloser List CME Internal Report
Presenter(s): 
Riley Caracci
Alyssa Guckenberger
Taylor Rough